SANTA CLARA, Calif., Oct. 24, 2023 /PRNewswire/ — ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a Canadian biotechnology company selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system – to digitize its corporate validation process.
The company provides early-stage contract development and manufacturing organization (CDMO) services to biotech clients, helping them bring their cell and gene therapies to market.
After applying sophisticated evaluation criteria that matched vendor capabilities with their demanding business needs, ValGenesis VLMS emerged as the clear winner. ValGenesis will implement ValGenesis VLMS for digital equipment qualification and validation at the company’s new 80,000+ sq. ft. facility due to open in early 2024.
“We are pleased to announce this new win from a partner referral, and we’re excited about the growth potential for ValGenesis through these relationships. With our new client opening a second site in 2025 and multiple sites across Europe and Australia, we will work alongside our partner to introduce them to new levels of collaboration and enterprise-wide visibility,” says Steve Reynolds, Chief Revenue Officer at ValGenesis. “Our SaaS-based solution was rigorously tested and earned their trust to create fully automated and transparent corporate validation processes that are standardized, optimized, and audit-ready. We look forward to an exciting journey ahead.”
ValGenesis, Inc. is the creator of an innovative software platform that is a foundation for managing compliance-based validation activities in life science companies. ValGenesis, Inc. is the provider of the first enterprise application that manages the corporate validation lifecycle process. This solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. As the first fully paperless solution for electronic management of validation execution and approval, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award in 2005. For more information, visit www.valgenesis.com
Althea D’Sylva, ValGenesis Communications, +1 510-445-0505 Ex.1026,
SOURCE ValGenesis Inc.